Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Depreivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer

Trial Profile

Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Depreivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Bicalutamide; Gonadotropin releasing hormone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Feb 2018 Results compared the combinations of enzalutamide or bicalutamide each with LHRH analogue therapy in metastatic hormone sensitive prostate cancer presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top